Market research
SDGR Schrodinger Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 21.4286
- Dividend yield
- Not available
- Beta
- 1.66
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- US80810D1037
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 21.4286
- Dividend yield
- Not available
- Beta
- 1.66
About
About Schrodinger Inc
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SDGR discussion.
5 years, 4 months ago
Schrödinger, Inc is currently in a long term uptrend where the price is trading 0.3% above its 200 day moving average.
From a valuation standpoint, the stock is 96.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.6.
Based on the above factors, Schrödinger, Inc gets an overall score of 2/5.